Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGC-Triple Regimen in Pancreatic Cancer
NCT03392571Phase 2Withdrawn
- Sponsor
- Pancreatic Cancer Research Team
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of nab-paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Pancreatic Cancer Research Team. Planned start Aug 2018; status: withdrawn.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03392571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392571.